Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement.
BACKGROUND
High-dose chemotherapy and stem cell transplantation are being applied increasingly to the treatment of selected patients with multiple myeloma or primary systemic amyloidosis. Stem cell transplantation presents unique challenges to the nephrologist because of the high prevalence of renal involvement in myeloma and the issues that are associated with high-dose chemotherapy in patients with the nephrotic syndrome due to renal amyloid.


METHODS
We review the published literature on stem cell transplantation in patients with reduced renal function.


CONCLUSIONS
The specifics of transplantation pertaining to patients with renal amyloid nephrotic syndrome are discussed in detail.
Gertz
Morie A
MA
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. gertz.morie@mayo.edu
Leung
Nelson
N
Lacy
Martha Q
MQ
Dispenzieri
Angela
A
D000686:Amyloidosis / Q000150:complications / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications / Q000628:therapy*; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D009404:Nephrotic Syndrome / Q000209:etiology / Q000628:therapy*
D019653:Myeloablative Agonists